NCT04923958Recruiting
Rapid Research in Diagnostics Development for TB Network
Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) Study
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
To reduce the burden of TB worldwide through more accurate, faster, simpler, and less expensive diagnosis of TB Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) brings together experts in TB care, technology assessment, diagnostics development, laboratory medicine, epidemiology, health economics and mathematical modeling with highly experienced clinical study sites in 10 countries.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 26436 (estimated)
- First submitted
- 7 Jun 2021
- Start date
- 14 Apr 2021
- Primary completion date
- 31 May 2031
- Lead sponsor
- University of California, San Francisco
- Diseases
- Tuberculosis
- NCT number
- NCT04923958
What you commit to
- Study type: Interventional
- Planned participants: 26436
- From 14 Apr 2021 to the primary completion date, 31 May 2031
- 16 sites in 8 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Novel TB triage and diagnostic tests:
- We will include non-hospitalized adults (age ≥ 12 years) with either 1) cough ≥2 weeks' duration, a commonly accepted criterion for identifying people with presumed pulmonary TB (to facilitate standardization across sites and comparison of test performance across sub-groups or 2) risk factors for which TB screening is recommended (HIV infection, self-reported close contact, history of mining work). People with risk factors will be included if they screen positive for TB based on WHO-recommended screening tools as specified below:
- Positive TB screening definitions by risk factor:
- PLHIV (Risk Factor), CRP \>5 mg/dL OR abnormal CXR (Positive TB screening definition)
- Self-reported Close Contact (Risk Factor), abnormal CXR (Positive TB screening definition)
- History of mining work (Risk Factor), abnormal CXR (Positive TB screening definition)
- We will exclude people who:
- completed latent or active TB treatment within the past 12 months (to increase TB prevalence and reduce false-positive results, respectively);
- have taken any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason, within 2 weeks of study entry (to reduce false-negatives);
- reside \>20km from the study site or are unwilling to return for follow-up visits; or
- are unwilling to provide informed consent
- Novel TB rDST assays:
- We will include adults (age ≥12 years) who are positive for TB and RIF resistance according to routine diagnostic testing (based typically on Xpert MTB/RIF, Xpert MTB/RIF Ultra, or Hain MTBDRplus). We will exclude people who:
- have negative or contaminated results on all baseline (i.e., enrollment) sputum cultures
- are unable to provide at least two sputum specimens of 3 mL each within one day of enrollment
- are unable or unwilling to provide informed consent
- Assessment of the usability of novel TB tests:
- We will include health workers at each clinical site who are 1) aged ≥18 years and 2) involved in routine TB testing (collecting specimens for or performing TB tests). We will exclude staff who are unwilling to provide informed consent.
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (16)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Center for Tuberculosis and Lung Diseases Coordinator of this site? Confirm its status | Tbilisi | Georgia | Recruiting |
| Primary care clinics (Shalom/LCC, CHAD) Coordinator of this site? Confirm its status | Vellore | India | Recruiting |
| Christian Medical College CMC Pulmonary Outpatient Department Coordinator of this site? Confirm its status | Vellore | India | Recruiting |
| Chitoor (Christian Medical College satellite campus) Coordinator of this site? Confirm its status | Vellore | India | Recruiting |
| Zankli Research Center Coordinator of this site? Confirm its status | Abuja | Nigeria | Recruiting |
| De La Salle Medical and Health Sciences Institute Coordinator of this site? Confirm its status | Dasmariñas | Philippines | Recruiting |
| Mulago Outpatient Department Coordinator of this site? Confirm its status | Kampala | Uganda | Recruiting |
| Kisenyi Health Center Coordinator of this site? Confirm its status | Kampala | Uganda | Recruiting |
| National Lung Hospital, Outpatient departments Coordinator of this site? Confirm its status | Hanoi | Vietnam | Recruiting |
| Hanoi Lung Hospital, Outpatient departments Coordinator of this site? Confirm its status | Hanoi | Vietnam | Recruiting |
| Kraaifontein Community Health Clinic Coordinator of this site? Confirm its status | Cape Town | South Africa | Recruiting |
| Khayelitsha District Health Center Coordinator of this site? Confirm its status | Cape Town | South Africa | Recruiting |
| Brooklyn Chest Hospital Coordinator of this site? Confirm its status | Cape Town | South Africa | Recruiting |
| Wallacedene primary care clinic Coordinator of this site? Confirm its status | Cape Town | South Africa | Recruiting |
| Scottsdene primary care clinic Coordinator of this site? Confirm its status | Cape Town | South Africa | Recruiting |
| Centre for Infectious Disease Research in Zambia Coordinator of this site? Confirm its status | Lusaka | Zambia | Recruiting |
Related publications
- Pulmonary Tuberculosis Detection with MiniDock MTB Using Swab Samples.N Engl J Med · 2026 · PMID 42054680
This page is information, not medical advice. Discuss any trial with your doctor.